
Home > R&D > Licensing Activities > Out Licensing
Main contents starts here
If we judge that a partner with excellent know-how can more effectively handle the matter depending on the target disease area or compound, we may select out-licensing on research, development, and/or sales of our own compounds by alliance without adhering to independent drug development by ourselves to provide excellent drugs to patients and medical service providers as early as possible.
| Licensee | Product Name or Development Code | Drug Class | Territory | Time |
| Indication(s) | ||||
| Tobira | TAK-220/TAK-652 | CCR5 Antagonists | World | Aug.07 |
| HIV Infection |